Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083707 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00083707 is a Phase 2 study of Waldenstrom Macroglobulinemia that has completed, run by University of Arkansas. The registered enrollment target is 40 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00083707, a Phase 2 study of Waldenstrom Macroglobulinemia, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/MIRT - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-01 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083707
The ClinicalTrials.gov registry entry for NCT00083707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00083707 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00083707 about?
NCT00083707 is a clinical study titled "Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia". The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
What is the current status of trial NCT00083707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1999-01. Estimated completion is 2003-02.
What conditions does trial NCT00083707 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT00083707?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083707?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083707 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.